Fibrinogen concentrate - Octapharma

Drug Profile

Fibrinogen concentrate - Octapharma

Alternative Names: Factor I concentrate; Octafibrin

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Octapharma
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Afibrinogenaemia

Most Recent Events

  • 30 Jan 2017 University Health Network, Toronto plans the phase III FIBRES (FIBrinogen REplenishment in Surgery) trial for Afibrinogenaemia in Canada (NCT03037424)
  • 03 Dec 2016 Interim safety and efficacy results from the phase III trial in Afibrinogenaemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 01 Dec 2015 Phase-III clinical trials in Afibrinogenaemia (In children, In infants) in Lebanon, Iran, India (IV) (NCT02408484)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top